Impact of discontinuation of antithrombotic therapy after surgery for chronic subdural hematoma.

Fiche publication

Date publication

août 2020

Journal

Neuro-Chirurgie

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CEBULA Hélène , Pr PROUST François

Tous les auteurs :
Todeschi J, Ferracci FX, Metayer T, Gouges B, Leroy HA, Hamdam N, Bougaci N, De Barros A, Timofeev A, Pretat PH, Bannwarth M, Roblot P, Peltier C, Lleu M, Pommier B, Chibbaro S, Proust F, Cebula H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32645393

Résumé

The management of antithrombotic therapy (AT) after surgery for chronic subdural hematoma (cSDH) requires taking account of the balance of risk between hemorrhage recurrence (HR) and the prophylactic thromboembolic effect (TE). The goal of the present study was to evaluate the prevalence of vascular events (VE: TE and/or HR) in the first 3 postoperative months after cSDH evacuation in patients previously treated by AT. The impact of AT resumption was also evaluated.